Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Analyst consensus: Five firms currently rate Generate Biomedicines "Buy"/"Overweight" with an average 1‑year target of $25 and published targets ranging from $20 (Morgan Stanley) to $30 (Guggenheim).
• Implied upside vs market: Those targets imply roughly 60%–140% upside, but GENB traded at $12.19 (down 2.7%) with volume of 50,185 versus an average of 693,201, leaving a notable gap between analyst views and current market pricing.
• Data caveat: Reported short‑interest figures for March appear corrupted (showing 0 shares/NaN ratios), so there is no reliable public short‑interest signal to explain recent intraday moves.

Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) has received an average recommendation of "Buy" from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $25.00.

Several research firms have recently issued reports on GENB. The Goldman Sachs Group assumed coverage on shares of Generate Biomedicines in a research note on Tuesday. They set a "buy" rating and a $26.00 price target for the company. Morgan Stanley assumed coverage on Generate Biomedicines in a report on Tuesday. They set an "overweight" rating and a $20.00 target price on the stock. Wall Street Zen raised Generate Biomedicines to a "hold" rating in a research note on Saturday, March 14th. Piper Sandler began coverage on Generate Biomedicines in a research note on Tuesday. They issued an "overweight" rating and a $24.00 price objective on the stock. Finally, Cantor Fitzgerald initiated coverage on Generate Biomedicines in a report on Tuesday. They issued an "overweight" rating on the stock.

More Generate Biomedicines News

Here are the key news stories impacting Generate Biomedicines this week:

• Positive Sentiment: Guggenheim initiated coverage with a "buy" rating and a $30.00 price target (≈139.6% upside), the highest published target among today's notes. Guggenheim Coverage
• Positive Sentiment: Goldman Sachs started coverage with a "buy" rating and a $26.00 price target (≈107.7% upside), another sizable bullish endorsement.
• Positive Sentiment: Piper Sandler initiated coverage with an "overweight" rating and a $24.00 price target (≈91.7% upside). Piper Sandler Coverage
• Positive Sentiment: Morgan Stanley initiated coverage with an "overweight" rating and a $20.00 price target (≈59.7% upside).
• Positive Sentiment: Cantor Fitzgerald initiated coverage with an "overweight" rating (no price target provided in the brief). Cantor Fitzgerald Coverage
• Neutral Sentiment: Reported short-interest data for March appears corrupted (shows 0 shares / NaN ratios), so there is no reliable public short-interest signal to explain intraday moves.

Generate Biomedicines Stock Down 2.7%

Shares of Generate Biomedicines stock traded down $0.33 on Tuesday, hitting $12.19. The stock had a trading volume of 50,185 shares, compared to its average volume of 693,201. Generate Biomedicines has a twelve month low of $11.00 and a twelve month high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.